The COVID Vaccine Pause: A Case for Greater Patient Engagement

In several early cases of J&J vaccine blood clotting, patients were treated with heparin, which is a normal treatment for blood clots; however, in these cases the heparin worsened the situation. The pause helped educate hospitals and health systems going forward on how to treat similar symptoms in those with the J&J dose.

Read More »

A Year of COVID-19 Data: Lessons Learned

Researchers have begun to dig into the results of this data collection and identified trends that have helped them understand mortality rates during the pandemic and beyond. BD recently published two papers on specific data discoveries during COVID-19, and Kalvin Yu, MD, FIDSA, senior medical director with BD, discusses some of the key takeaways from that research.

Read More »

New CMS Vaccines Rule Soon May Apply to More Facilities

The changes to the Conditions of Participation (CoP) for those facilities primarily require vaccines to be offered to residents, clients, and staff when available. They also set education and CDC reporting requirements. While the rule covers only those two types of facilities so far, CMS notes in the rule it may want to expand those requirements to other healthcare organizations, including psychiatric hospitals and inpatient hospice facilities.

Read More »

The Clinical Relevance of COVID-19 Testing Amid the Rollout of the Vaccine

From a medical point of view, there are five primary variables that will affect long-term demand for COVID-19 rapid antigen testing: pace of vaccination (U.S. and global); reaching a 70%–80% vaccinated population nationwide; reported case rate (U.S. and global); duration of the vaccine’s effectiveness in an individual (currently unknown); and the mutation rate of COVID-19 variants.

Read More »